Shire pharmaceutical valued at £30bn in new AbbVie bid

US pharma giant seeks to buy Dublin-based Shire to optimise tax in move reminiscent of Pfizer’s failed pursuit of AstraZeneca

Pharmaceutical company Shire has been valued at £30bn in a raised bid from the US rival which has been trying to take control of the business for weeks.

The chairman of Chicago-based AbbVie urged Shire shareholders to back its fourth offer for the FTSE 100 company, which is best known for its controversial treatment for attention deficit hyperactivity disorder (ADHD).

Continue reading…
Pharmaceuticals industry | The Guardian

Pharmaceutical Stocks


© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us